

Cite this: *Chem. Sci.*, 2023, 14, 5062

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Synthesis of biolabile thioalkyl-protected phosphates from an easily accessible phosphotriester precursor†

Lloyd D. Murphy,<sup>a</sup> Kathryn E. Huxley,<sup>a</sup> Ava Wilding,<sup>b</sup> Cyane Robinson,<sup>b</sup> Quentin P. O. Foucart<sup>a</sup> and Lianne I. Willems<sup>a\*</sup>

Robust methods for the synthesis of mixed phosphotriesters are essential to accelerate the development of novel phosphate-containing bioactive molecules. To enable efficient cellular uptake, phosphate groups are commonly masked with biolabile protecting groups, such as *S*-acyl-2-thioethyl (SATE) esters, that are removed once the molecule is inside the cell. Typically, bis-SATE-protected phosphates are synthesised through phosphoramidite chemistry. This approach, however, suffers from issues with hazardous reagents and can give unreliable yields, especially when applied to the synthesis of sugar-1-phosphate derivatives as tools for metabolic oligosaccharide engineering. Here, we report the development of an alternative approach that gives access to bis-SATE phosphotriesters in two steps from an easy to synthesise tri(2-bromoethyl) phosphotriester precursor. We demonstrate the viability of this strategy using glucose as a model substrate, onto which a bis-SATE-protected phosphate is introduced either at the anomeric position or at C6. We show compatibility with various protecting groups and further explore the scope and limitations of the methodology on different substrates, including *N*-acetylhexosamine and amino acid derivatives. The new approach facilitates the synthesis of bis-SATE-protected phosphoproboscopes and prodrugs and provides a platform that can boost further studies aimed at exploring the unique potential of sugar phosphates as research tools.

Received 8th February 2023  
Accepted 19th April 2023

DOI: 10.1039/d3sc00693j


rsc.li/chemical-science

## Introduction

Glycans are a structurally diverse class of biomolecules that play essential roles in diverse biological and pathological processes. Metabolic oligosaccharide engineering (MOE) has emerged as a powerful approach to characterise and manipulate glycan function in a native context.<sup>1</sup> In MOE, chemical tags or other modifications are introduced into glycan structures by treating living cells or organisms with unnatural carbohydrate derivatives, which are metabolised by the cell's natural biosynthetic machinery into the activated sugar nucleotides required for glycosylation. A prerequisite for the success of this approach is that the unnatural carbohydrates are efficiently taken up inside the cell.<sup>2–5</sup> With a few exceptions,<sup>6,7</sup> the cellular entry mechanism of MOE probes is generally assumed to involve passive diffusion. Therefore, these probes are typically designed as caged precursors which are able to cross the cell membrane more efficiently and carry biolabile

protecting groups that can be cleaved by endogenous intracellular enzyme activity to release the bioactive molecules.<sup>2,8</sup>

Most MOE approaches make use of unnatural analogues of monosaccharides, such as azide- or alkyne-tagged derivatives of *N*-acetylglucosamine (GlcNAc). Several phosphorylated monosaccharide derivatives have, however, shown significantly improved MOE efficiency by bypassing problematic steps in the cellular biosynthetic pathways towards the corresponding sugar



**Fig. 1** Biolabile *S*-acyl-2-thioethyl protecting groups enable intracellular delivery of phosphate-containing bioactive molecules from masked precursors, such as the tagged GlcNAc-1-phosphate derivative shown (with 'tag' representing a photoaffinity label<sup>8</sup> or fluorophore,<sup>9</sup> for example). Once inside the cell, the free phosphate is released through esterase-mediated hydrolysis of the thioesters followed by spontaneous decomposition of the resulting mercaptoethyl groups.

<sup>a</sup>York Structural Biology Laboratory and York Biomedical Research Institute, Department of Chemistry, University of York, York YO10 5DD, UK. E-mail: lianne.willems@york.ac.uk

<sup>b</sup>Department of Chemistry, University of York, York YO10 5DD, UK

† Electronic supplementary information (ESI) available: Optimisation data, experimental procedures and NMR spectra of all new compounds. See DOI: <https://doi.org/10.1039/d3sc00693j>



nucleotide donors.<sup>8–12</sup> To enable efficient cellular uptake, the phosphates on these probes are typically masked with two *S*-acyl-2-thioethyl (SATE) protecting groups, as shown for a tagged GlcNAc-1-phosphate derivative in Fig. 1.

First described for the intracellular delivery of nucleoside 5'-monophosphate derivatives of an anti-HIV drug,<sup>13</sup> SATE protection is still commonly used as a prodrug strategy for nucleoside monophosphates and phosphonates.<sup>14,15</sup> The biological instability of SATE groups is attributed to hydrolysis of the thioesters by carboxy- or thioesterase activity naturally present in mammalian cells.<sup>13,16</sup> The resulting mercaptoethyl groups are presumed to spontaneously decompose by an intramolecular nucleophilic displacement mechanism that generates ethylene disulfide and releases the desired phosphate monoester (Fig. 1).

SATE-protected sugar phosphates are typically synthesised from a bis-SATE phosphoramidite intermediate (**1**), which in turn is prepared from the highly reactive reagent diisopropylphosphoramidous dichloride (Scheme 1A, top panel).<sup>13</sup> Reaction of **1** with a substrate alcohol in the presence of 1*H*-tetrazole gives a phosphite, which is further oxidised to obtain the bis-SATE-protected phosphoester. Aside from the issue that diisopropylphosphoramidous dichloride is not commercially available in some countries including the UK, necessitating synthesis and isolation of the hazardous reagent, this methodology also suffers from low and inconsistent yields, particularly when used in the context of sugar-1-

phosphates.<sup>9,10,17–19</sup> Recently, a modification to the phosphoramidite approach, starting from a commercially available bis(diisopropylamino)chlorophosphine reagent, was shown to improve the synthesis of a SATE-protected GlcNAc-1-phosphate derivative.<sup>19</sup>

A different strategy was reported to solve issues with the preparation of an *S*-pivaloyl-2-thioisopropyl phosphoramidite reagent needed for the synthesis of caged mononucleoside derivatives.<sup>20</sup> Starting from a substrate monophosphate, the required thioalkyl-protected phosphotriester was generated *via* esterification either directly with the required thioalkyl groups or *via* bromoalkyl intermediate **2** (Scheme 1A, bottom panel). In this work, we develop an alternative method for the synthesis of SATE-protected mixed phosphotriesters that does not require the initial installation of a phosphomonoester onto the substrate, while avoiding the use of reactive phosphoramidite intermediates.


Our approach is based on recent reports showing that mixed phosphates and phosphonates can be accessed through triflic anhydride-mediated activation of a trialkylphosph(on)ate.<sup>21,22</sup> Key to these strategies was the selective monosubstitution of one of the phosphoester groups. We hypothesised that we could use a similar strategy for the synthesis of bis-SATE-protected phosphates from the precursor tri(2-bromoethyl)phosphate (**3**) (Scheme 1B). Here, we describe the development of this approach, which involves triflic anhydride/pyridine-mediated selective monosubstitution of phosphotriester **3** by the free

#### A) Previous work on bis-SATE-protected phosphate synthesis

##### common approach using a phosphoramidite precursor




##### alternative: bis-bromoalkyl intermediate accessible through monophosphate esterification



#### B) This work

##### key step: monosubstitution of a tri(2-bromoethyl)phosphate precursor



**Scheme 1** Synthesis of bis-SATE protected phosphates. (A) The common approach for bis-SATE phosphotriester synthesis involves reaction of a substrate (R–OH) with phosphoramidite **1**, followed by oxidation. Alternatively, after introduction of a monophosphate onto a substrate, a bis-bromoalkyl phosphotriester intermediate **2** can be formed through esterification and the bromides subsequently substituted for thioacyl groups.<sup>20</sup> (B) In this work, we describe a two-step approach involving triflic anhydride/pyridine-mediated selective monosubstitution of tri(2-bromoethyl) phosphate precursor **3** by a substrate, followed by substitution of the bromides for thioacetates.



hydroxyl group of a substrate, followed by substitution of the bromides for thioacetate groups. We demonstrate the feasibility of this strategy for the synthesis of bis-SATE-protected sugar phosphates and further explore the scope and compatibility of the methodology on a range of substrates with diverse protecting groups.

## Results and discussion

Prompted by the reported difficulties with phosphoramidite chemistry for SATE-protected sugar phosphate synthesis, we decided to perform the validation and optimisation of our new methodology on glucose as a model substrate. C1- and C6-phosphorylated pyranose sugars occur naturally within cellular metabolic pathways towards the biosynthesis of glycosylation donors. Of these two positions, the primary hydroxyl group at C6 is most nucleophilic and sterically accessible. Moreover, SATE-protected glucose-6-phosphate derivatives have been described as pro-inhibitors for intracellular carbonic anhydrase activity.<sup>23</sup>

We thus began our method development with the installation of a bis-SATE-protected phosphate at the C6 position of 1,2,3,4-tetra-*O*-benzylglucopyranoside **5** (Scheme 2). Initially, we aimed to install the thioalkyl-protected phosphate directly onto **5** in one step by using a phosphotriester precursor already equipped with the required SATE groups (**4**). We were able to synthesise this precursor (**4**) *via* a straightforward two-step procedure from the commercially available reagents POCl<sub>3</sub>, 2-bromoethanol and potassium thioacetate. Both reagent **4** and the bromoalkyl intermediate **3** were readily produced with good yields on a gram scale. Subsequent reaction of glucose substrate **5** with precursor **4** in the presence of triflic anhydride and pyridine was, however, not successful (Scheme 2). Despite being


able to detect the desired bis-SATE-protected phosphate **6** by mass spectrometry, we could not isolate any product.

As an alternative, in line with the approach shown in Scheme 1A,<sup>20</sup> we attempted to install a phosphate masked with two bromoalkyl groups onto the glucose substrate first, prior to substitution of the bromides for thioacetates. The triflic anhydride/pyridine-mediated reaction of **5** with tri(2-bromoethyl)phosphate **3** successfully yielded intermediate **7** in 13% yield (Scheme 2). The bis-SATE-protected phosphate **6** was then quantitatively obtained through a substitution reaction with potassium thioacetate.

Having demonstrated the viability of our new two-step approach, we set out to optimise the reaction conditions using the more readily available substrate 3-phenylpropanol (Table S1 in the ESI†). We found that the introduction of a 10 minute preactivation time, during which the phosphate precursor **3** is reacted with triflic anhydride (Scheme 1B, step 1i) before the addition of pyridine (step 1ii), greatly increased yields. It is also important to note that the use of freshly distilled triflic anhydride and fresh anhydrous pyridine is important to achieve reproducible results. Overall, we were able to increase the yield of the incorporated bis-(2-bromoethyl) phosphate from 17% to 51% after optimisation (Table S1,† entry 2). On increasing the preactivation time further, a reduction in yield was observed, suggesting instability of the intermediate phospho-triflate species in solution. Similarly, we observed a drop in yield when the reaction mixture was left for more than 10 minutes between the addition of pyridine (Scheme 1B, step 1ii) and the substrate (step 1iii).


Moving back to our model carbohydrate substrate, we applied the optimised reaction conditions to the reaction of partially protected glucose derivative **5** with phosphotriester **3**. Pleasingly, we found the yield of bis-(2-bromoethyl)-protected phosphate **7** to be improved from 13% to 31% (Table S2,† entry 1). We then tested the effect of increasing the reaction time after addition of the sugar substrate to the preactivated phosphotriester/triflic anhydride/pyridine mixture (Scheme 1B, step 1iii). The results (Table S2†) show that further increases in yield were achieved with increasing reaction time, doubling from 31% after 30 minutes to 62% at an optimal reaction time of 1.5 hours (entry 3). The main carbohydrate by-product we observed was identified as a triflated species that can be hydrolysed back to starting material (see ESI†).

Next, we aimed to explore the compatibility and efficiency of the reaction on a small panel of differently protected glucose derivatives. In addition to the benzyl ether-protected substrate used above (**5**), we also tested glucose derivatives protected with allyl ethers (**8a**), acetyl esters (**8b**), and benzoyl esters (**8c**) under the same reaction conditions (Table 1). Installation of the bis-SATE-protected phosphate at the C6 position was successful for all tested substrates, with each reaction producing reproducible results across at least two independent replicates. Yields for the phosphoester substitution reaction (step 1) were somewhat lower for the allyl- and benzoyl-protected substrates **8a** and **8c**, respectively (32–37%) while the acetylated (**8b**) and benzylated (**5**) substrates reacted more efficiently (56–61%). The subsequent thioacetate substitution (step 2) proceeded



Scheme 2 Installation of a bis-SATE-protected phosphate at C6 of 1,2,3,4-tetra-*O*-benzylglucopyranoside. Initial yields are shown prior to optimisation of reaction conditions.



**Table 1** Synthesis of bis-SATE-protected phosphate esters at C6 of differently protected glucose derivatives<sup>a</sup>



Substrate	Yields (%) <sup>b</sup>		Overall
	Step 1	Step 2	
<b>5</b> R <sup>1</sup> = Bn	61%	Quant	61%
<b>8a</b> R <sup>1</sup> = allyl <sup>c</sup>	32%	Quant	32%
<b>8b</b> R <sup>1</sup> = Ac	56%	55%	31%
<b>8c</b> R <sup>1</sup> = Bz	37%	Quant	37%

<sup>a</sup> Reaction conditions: step (1) (i) **3**, Tf<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, RT, 10 min., (ii) pyridine, RT, 10 min., (iii) **5**, **8a**, **8b** or **8c**, RT, 1.5 h; step (2) KSAC, pyridine, RT, 18 h. <sup>b</sup> Yields are reported as averages of duplicate reactions. Overall yield represents the combined yield over steps 1 and 2. <sup>c</sup> The product could not be fully separated from unreacted reagent **3**. Yields were calculated from relative integration of characteristic signals on <sup>1</sup>H NMR.

quantitatively for all substrates except the acetyl-protected derivative, which surprisingly yielded only 55% of purified product. Overall, the reaction remained most successful on benzylated substrate **5**, which provides access to bis-SATE-protected glucose-6-phosphate derivative **6** in a reproducible yield of around 60% over both steps.

Encouraged by these promising results, we extended our strategy to the installation of a bis-SATE-protected phosphate at the anomeric position of a set of appropriately protected glucose derivatives (Table 2). Initially, step 2 was performed with KSAC in acetone as before (Scheme 2). This resulted in low conversion to thioalkyl product, while the lack of recoverable starting material suggested that degradation was taking place. Therefore, we explored alternative solvents for the substitution step, which led to significantly improved results (Table S3<sup>†</sup>). The use of pyridine provided the highest conversion into thioester product and enabled the successful isolation of bis-SATE-protected glucose-1-phosphate derivatives of **9a-d** in overall yields ranging from 14% to 30% over both steps (Table 2).

Analysis of the anomeric product ratios after the two-step procedure revealed that most reactions favoured formation of the  $\alpha$ -anomeric phosphate, the anomer that generally acts as a direct metabolic precursor for sugar nucleotide biosynthesis and would thus be desired in the context of MOE. An exception is the acetylated substrate **9c**, which showed a slight preference for the  $\beta$ -anomer, leading to an equimolar mixture of anomeric products. Benzyl-protected substrate **9a** gave full  $\alpha$  selectivity. Finally, we performed the reaction with substrate **9c** on a gram scale and obtained essentially the same yield (25% over two steps), demonstrating the excellent scalability of the approach.

**Table 2** Synthesis of bis-SATE-protected anomeric phosphate esters of differently protected glucose derivatives<sup>a</sup>



Substrate	Yields (%)			Anomeric ratio <sup>c</sup> $\alpha$ : $\beta$ (s.m.)
	Step 1	Step 2	Overall <sup>b</sup>	
<b>9a</b> R <sup>1</sup> = Bn	26%	78%	20%	1 : 0 (2 : 1)
<b>9b</b> R <sup>1</sup> = allyl	20%	72%	14%	3 : 1 (4 : 1)
<b>9c</b> R <sup>1</sup> = Ac	33%	72%	24%	1.2 : 1 (4 : 1)
<b>9d</b> R <sup>1</sup> = Bz	41%	74%	30%	5 : 1 (4 : 1)

<sup>a</sup> Reaction conditions: step (1) (i) **3**, Tf<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, RT, 10 min., (ii) pyridine, RT, 10 min., (iii) **9a-d**, RT, 1.5 h; step (2) KSAC, pyridine, RT, 18 h. <sup>b</sup> Overall yield represents the combined yield over steps 1 and 2. <sup>c</sup> Anomeric ratios were determined from the relative integration of anomeric proton peaks in the <sup>1</sup>H NMR spectra of the products after step 2. Numbers in parentheses represent the anomeric ratio of the starting material (s.m.).

Aiming to push the boundaries of our new synthetic strategy further, we shifted our focus towards *N*-acetylhexosamines, substrates that provide additional challenges due to the presence of the *N*-acyl group capable of forming a 1,2-oxazoline through neighbouring group participation. Several SATE-protected *N*-acetylhexosamine-1-phosphate derivatives have been developed as MOE reporters.<sup>8-12</sup> Therefore, we attempted to perform our phosphorylation strategy on 3,4,6-tri-*O*-acetylated GlcNAc **10** and its tribenzylated analogue **11** (Scheme 3). Unfortunately, these reactions were unsuccessful and only starting material could be isolated. We were also unable to detect any product from the reaction on 6-azido-tagged GlcNAc derivative **12**.

Because GlcNAc donors are notorious for forming oxazolines or oxazolinium ions during glycosylation reactions,<sup>24</sup> we hypothesised that oxazoline formation might be hindering reaction progress. We therefore monitored the reaction with substrate **10** by <sup>1</sup>H NMR and indeed observed formation of an oxazolinium ion (Fig. S1<sup>†</sup>) as soon as 5 minutes after the start of the reaction. This observation was supported by high resolution mass spectrometry data, confirming the presence of an oxazoline (Fig. S2<sup>†</sup>) alongside unreacted **10**. Interestingly, when we tested the *N*-azido-acetylated analogue **13** we observed low but detectable levels of product formation and were able to isolate the bis-SATE-protected phosphate in 9% yield (Scheme 3). We speculated that electronic effects might cause the higher reactivity of **13** as compared to **10**, with the azide in **13** deactivating the *N*-acyl group and thereby reducing the probability of oxazolinium ion formation. To test this possibility, we prepared the electron-withdrawing trichloroacetyl derivative **14**. Surprisingly, we observed no reaction with this substrate under the optimised reaction conditions (Scheme 3, conditions A).





**Scheme 3** Extending the scope of the bis-SATE-protected phosphate synthesis methodology. The two-step reaction procedure was applied to various GlcNAc derivatives (**10–15**) and amino acid analogues (**16–21**). Yields are shown following either the optimised procedure (A) or the adapted protocol with the addition of triethylamine (B) and represent overall yields over both steps of the reaction unless indicated otherwise. \*Preactivation conditions: (i) **3**,  $\text{Tf}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ , RT, 10 min., (ii) pyridine, RT, 10 min. #: Yield of bis-(2-bromoethyl)-phosphate intermediate after step 1.

While these data support the hypothesis that oxazolinium ion formation is hindering efficient anomeric phosphorylation of GlcNAc substrates under the triflic anhydride/pyridine-promoted reaction conditions, further experimentation is required to fully understand the lack of reaction with these substrates and the mechanism leading to formation of an oxazoline or oxazolinium species remains elusive. The activation of anomeric glycosyl phosphotriesters using triflic acid (a by-product of our tri(2-bromoethyl)phosphate activation procedure) as a promoter has been reported previously.<sup>25,26</sup> However, we have not been able to observe the formation of any phosphotriester product that could act as a potential intermediate towards an oxazoline. Furthermore, we detected oxazoline formation by  $^1\text{H}$  NMR upon treatment of **10** with triflic anhydride and pyridine alone, in the absence of phosphotriester **3**, supporting a potential mechanism independent of anomeric phosphate installation (Fig. S1†). Nevertheless, when trialling the addition of triethylamine into the phosphorylation reaction to neutralise any triflic acid that was being formed (Scheme 3, conditions B), the trichloroacetyl derivative **14** was converted successfully into the bis-(2-bromoethyl)phosphate intermediate in 39% yield. Unfortunately, the same conditions did not result in notable changes to the reaction outcome for substrates **10** and **13**. We also attempted to vary the concentration of the reactants and the molar equivalents of triflic anhydride and pyridine in the reaction with **10**, but this did not lead to successful phosphotriester formation.

Synthesis of GlcNAc-containing glycoconjugates often involves installation of an azide at C2 as a temporary masking group. This strategy has previously been used to synthesise a fluorescent, GlcNAc-1-phosphate-derived MOE probe: after

installation of a bis-SATE-protected anomeric phosphate onto 2-deoxy-2-azido GlcNAc **15** (Scheme 3), the amide functionality was regained through selective reduction of the azide with concomitant *N*-acylation.<sup>9</sup> To explore if the same strategy could also give access to bis-SATE-protected GlcNAc-1-phosphate derivatives using our new methodology, we applied our optimised two-step reaction sequence to compound **15**. This reaction was successful and yielded a satisfying 36% of bis-SATE-protected phosphotriester with the  $\alpha$  anomer being the major product (7 : 1 ratio to  $\beta$  anomer), comparing well with the 25% yield previously reported for its synthesis *via* phosphoramidite chemistry.<sup>9</sup> The resulting bis-SATE-protected 2-azidosugar phosphate can be converted into GlcNAc-1-phosphate derivatives as reported.<sup>9</sup>

Finally, we turned our attention to the phosphorylation of amino acids. We selected a small set of phospho-serine and -tyrosine analogues to test our new methodology. This also enabled us to explore compatibility with additional protecting groups, including Boc, Fmoc and Cbz. The Fmoc, CBz and allyl protecting groups in tyrosine mimics **17**, **18** and **19** were well tolerated, giving yields between 31% and 52% (Scheme 3). Initial attempts with the Boc-protected substrate **16** resulted in cleavage of the Boc group, likely due to triflic acid formation during the reaction. When repeated in the presence of triethylamine (conditions B), however, we successfully obtained the desired product in 18% yield. For allyl-protected derivative **20**, installation of the bis-(2-bromoethyl)phosphate was successful (55%) but we detected loss of the phosphate group during thioacetate treatment. This might be caused by bromide substitution at the benzylic carbon in a manner analogous to the reported chloride-mediated cleavage of benzyl groups during



phosphotriester synthesis with POCl<sub>3</sub>.<sup>27</sup> Lastly, installation of the protected phosphate onto Boc-protected serine derivative **21** was successful in the presence of base. These results demonstrate the viability of our new approach for the preparation of bis-SATE-protected phospho-amino acids.

## Conclusions

We have developed a novel approach for the synthesis of bis-SATE-protected phosphates that avoids the use of unstable phosphoramidite precursors. The reaction involves triflic anhydride/pyridine-mediated activation of a tri(bromoalkyl) phosphotriester precursor that can be easily prepared from phosphoryl chloride on a large scale. With this strategy, we facilitate straightforward access to biologically relevant phosphotriesters with biolabile thioalkyl protecting groups. We successfully applied the new methodology to the synthesis of SATE-protected sugar phosphates and phospho-amino acid derivatives and demonstrated it to be compatible with a range of commonly used protecting groups. In addition to its potential impact on the development of SATE-protected prodrugs,<sup>14,15</sup> the approach offers a valuable extension to the available toolkit for the synthesis of phosphorylated saccharides.<sup>28</sup> By tuning the ester groups on the phosphotriester precursor, different types of mixed phosphates should also be within reach. In particular, our new synthetic route towards SATE-protected sugar-1-phosphates has great potential to boost the development of novel phosphorylated metabolic precursors as MOE probes for the study of glycan structure and function.

## Experimental procedures

Compounds **9a**,<sup>29</sup> **9b**,<sup>30</sup> **9c**,<sup>31</sup> **9d**,<sup>32</sup> **10**,<sup>33</sup> **13**,<sup>9</sup> **14**,<sup>34</sup> **16**,<sup>27</sup> **17**,<sup>27</sup> **18**,<sup>27</sup> **19**,<sup>27</sup> **20**,<sup>27</sup> and **21**<sup>35</sup> were synthesised as described previously and characterisation data were found to be in accordance with the literature. Compound **15** was synthesised through an adapted literature procedure<sup>9</sup> with the azido transfer reagent made *in situ*.<sup>36</sup> Characterisation data matched those described previously.<sup>9</sup> Experimental procedures and NMR spectra for all new compounds are provided in the ESI.†

## Data availability

All data associated with this publication are provided in the ESI.†

## Author contributions

This study was conceptualised by LIW and KEH. LDM and LIW co-wrote the manuscript with input from KEH. Compounds were synthesised and characterised by LDM, KEH, AW, CR and QPOF under supervision of LIW. KEH performed initial testing and optimisation of the methodology. LDM explored the substrate scope and validated the main findings. LIW acquired and managed the funding to support the work.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [Grant agreement No 851448]. The authors would like to thank Gideon Davies and Martin Fascione for valuable input and Natasha Hatton for providing 3,4,6-tri-O-acetyl-2-deoxy-2-trichloroacetamido- $\alpha/\beta$ -D-glucopyranose.

## References

- For recent reviews, see: (a) N. Nischan and J. J. Kohler, *Glycobiology*, 2016, **26**, 789; (b) T. J. Sminia, H. Zuilhof and T. Wennekes, *Carbohydr. Res.*, 2016, **435**, 121; (c) P. A. Gilormini, A. R. Batt, W. R. Pratt and C. Biot, *Chem. Sci.*, 2018, **9**, 7585; (d) M. Kuffleitner, L. M. Haiber and V. Wittmann, *Chem. Soc. Rev.*, 2023, **52**, 510; (e) K. E. Huxley and L. I. Willems, *Biochem. Soc. Trans.*, 2021, **49**, 903.
- A. K. Sarkar, T. A. Fritz, W. H. Taylor and J. D. Esko, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 3323.
- B. E. Collins, T. J. Fralich, S. Itonori, Y. Ichikawa and R. L. Schnaar, *Glycobiology*, 2000, **10**, 11.
- M. B. Jones, H. Teng, J. K. Rhee, N. Lahar, G. Baskaran and K. J. Yarema, *Biotechnol. Bioeng.*, 2004, **85**, 394.
- N. D. Pham, C. S. Fermaintt, A. C. Rodriguez, J. E. McCombs, N. Nischan and J. J. Kohler, *Glycoconjugate J.*, 2015, **32**, 515.
- P. A. Gilormini, C. Lion, D. Vicogne, T. Levade, S. Potelle, C. Mariller, Y. Guérardel, C. Biot and F. Foulquier, *Chem. Commun.*, 2016, **52**, 2318.
- M. Bardor, D. H. Nguyen, S. Diaz and A. Varki, *J. Biol. Chem.*, 2005, **280**, 4228.
- S. H. Yu, M. Boyce, A. M. Wands, M. R. Bond, C. R. Bertozzi and J. J. Kohler, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 4834.
- H. Y. Tan, R. Eskandari, D. Shen, Y. Zhu, T.-W. Liu, L. I. Willems, M. G. Alteen, Z. Madden and D. J. Vocadlo, *J. Am. Chem. Soc.*, 2018, **140**, 15300.
- B. Schumann, *et al.*, *Mol. Cell*, 2020, **78**, 824.
- M. F. Debets, *et al.*, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 25293.
- A. Cioce, *et al.*, *ACS Chem. Biol.*, 2021, **16**, 1961.
- (a) C. Périgaud, G. Gosselin, I. Lefebvre, J.-L. Girardet, S. Benzaria, I. Barber and J.-L. Imbach, *Bioorg. Med. Chem. Lett.*, 1993, **3**, 2521; (b) I. Lefebvre, C. Périgaud, A. Pompon, A. M. Aubertin, J. L. Girardet, A. Kirn, G. Gosselin and J. L. Imbach, *J. Med. Chem.*, 1995, **38**, 3941.
- U. Pradere, E. C. Garnier-Amblard, S. J. Coats, F. Amblard and R. F. Schinazi, *Chem. Rev.*, 2014, **114**, 9154.
- Z. Xie, L. Lu, Z. Wang, Q. Luo, Y. Yang, T. Fang, Z. Chen, D. Ma, J. Quan and Z. Xi, *Eur. J. Med. Chem.*, 2022, **243**, 114796.
- B. R. Meade, *et al.*, *Nat. Biotechnol.*, 2014, **32**, 1256.



- 17 J. F. A. Pijnenborg, E. A. Visser, M. Noga, E. Rossing, R. Veizaj, D. J. Lefeber, C. Büll and T. J. Boltje, *Chemistry*, 2021, **27**, 4022.
- 18 J. F. A. Pijnenborg, E. Rossing, J. Merx, M. J. Noga, W. H. C. Titulaer, N. Eerden, R. Veizaj, P. B. White, D. J. Lefeber and T. J. Boltje, *Nat. Commun.*, 2021, **12**, 7024.
- 19 B. N. Kakde, E. Capota, J. J. Kohler and U. K. Tambar, *J. Org. Chem.*, 2021, **86**, 18257.
- 20 S. Peyrottes, C. Périgaud, A.-M. Aubertin, G. Gosselin and J.-L. Imbach, *Antiviral Chem. Chemother.*, 2001, **12**, 223.
- 21 H. Huang, J. Ash and J. Y. Kang, *Org. Lett.*, 2018, **20**, 4938.
- 22 P. Adler, A. Pons, J. Li, J. Heider, B. R. Brutiu and N. Maulide, *Angew. Chem., Int. Ed.*, 2018, **57**, 13330.
- 23 G. M. Rankin, D. Vullo, C. T. Supuran and S.-A. Poulsen, *J. Med. Chem.*, 2015, **58**, 7580.
- 24 M. H. S. Marqvorsen, M. J. Pedersen, M. R. Rasmussen, S. K. Kristensen, R. Dahl-Lassen and H. H. Jensen, *J. Org. Chem.*, 2017, **82**, 143.
- 25 O. J. Plante, E. R. Palmacci, R. B. Andrade and P. H. Seeberger, *J. Am. Chem. Soc.*, 2001, **123**, 9545.
- 26 R. Arihara, K. Kakita, N. Suzuki, S. Nakamura and S. Hashimoto, *J. Org. Chem.*, 2015, **80**, 4259.
- 27 C. D. Spicer, M. Pujari-Palmer, H. ne Autefage, G. Insley, P. Procter, H. Engqvist and M. M. Stevens, *ACS Cent. Sci.*, 2020, **6**, 226.
- 28 N. Wang, Y. Kong, J. Li, Y. Hu, X. Li, S. Jiang and C. Dong, *Bioorg. Med. Chem.*, 2022, **68**, 116806.
- 29 M. A. Fernández-Herrera, S. Mohan, H. López-Muñoz, J. M. V. Hernández-Vázquez, E. Pérez-Cervantes, M. L. Escobar-Sánchez, L. Sánchez-Sánchez, I. Regla, B. M. Pinto and J. Sandoval-Ramírez, *Eur. J. Med. Chem.*, 2010, **45**, 4827.
- 30 P. Wei, D. Zhang, Z. Gao, W. Cai, W. Xu, L. Tang and G. Zhao, *Synth. Commun.*, 2015, **45**, 1457.
- 31 S. Kim and P. Nagorny, *Org. Lett.*, 2022, **24**, 2294.
- 32 S. Yin, L. Li, L. Su, H. Li, Y. Zhao, Y. Wu, R. Liu, F. Zou and G. Ni, *Carbohydr. Res.*, 2022, **517**, 108575.
- 33 C. A. Kondor, J. N. Gorantla, G. D. Leonard and C. Fehl, *Bioorg. Med. Chem.*, 2022, **70**, 11691.
- 34 N. Barroca-Aubry, A. Pernet-Poil-Chevrier, A. Domard and S. Trombotto, *Carbohydr. Res.*, 2010, **345**, 1685.
- 35 S. Bregant and A. B. Taylor, *J. Org. Chem.*, 2005, **70**, 2430.
- 36 H. Ye, R. Liu, D. Li, Y. Liu, H. Yuan, W. Guo, L. Zhou, X. Cao, H. Tian, J. Shen and P. G. Wang, *Org. Lett.*, 2013, **15**, 18.

